[Asia Economy Reporter Hyunseok Yoo] Naivek, a peptide fusion bio-specialized company, announced on the 30th that it has received gene drugs from Japan's Daiichi Sankyo, with whom it is conducting joint research, and has started new drug development.
Naivek held an official kickoff meeting with Daiichi Sankyo, received the candidate gene drug from Daiichi Sankyo, and began full-scale research. This joint research contract focuses on developing new drugs by combining Daiichi Sankyo's gene candidate substances with Naivek's 'NIPEP-TPP based targeted tissue penetration drug delivery system.'
Naivek has already started full-scale research based on the candidate gene substances sent from Daiichi Sankyo. The candidate substances from Daiichi Sankyo will be conjugated to NIPEP-TPP, and verification at the in-vitro stage, including stability and cell penetration tests, will be conducted.
A Naivek official stated, "We held a kickoff meeting attended by researchers and staff from both Daiichi Sankyo and Naivek, and Naivek's overseas business development advisor traveled from Switzerland to Korea to attend this kickoff meeting in person."
He added, "With the visit of the overseas business development advisor who is promoting partnerships with global pharmaceutical companies, the kickoff meeting with Daiichi Sankyo was successfully conducted. We also held meetings and strategic consultations with several global pharmaceutical companies. Naivek is expected to receive the first phase of research and development funds from Daiichi Sankyo soon, and we will make every effort to achieve the best results," he emphasized.
Naivek is conducting joint research related to anticancer therapies as well as gene delivery systems related to the NIPEP-TPP drug delivery platform, and is currently pursuing technical discussions.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
